Bharat Biotech Indigenous Vaccine Platform

Bharat Biotech, based in Hyderabad, developed Covaxin (BBV152) — the world's first whole-virion inactivated COVID-19 vaccine, developed entirely in India in collaboration with the Indian Council of Medical Research (ICMR). Unlike SII's Covishield (licensed from Oxford), Covaxin was a fully indigenous development, demonstrating India's capability to develop novel vaccines from basic research through manufacturing.

Bharat Biotech has over 16 vaccines in its portfolio, including the world's first typhoid conjugate vaccine (Typbar-TCV) and a rotavirus vaccine (ROTAVAC) — both WHO-prequalified. The company has manufacturing capacity for 4.5+ billion vaccine doses annually and supplies vaccines to over 125 countries.

Bharat Biotech's significance lies in proving India can do original vaccine R&D, not just license-and-manufacture from Western companies. The company's intranasal COVID vaccine (iNCOVACC) was the world's first intranasal COVID vaccine approved for primary immunization. This innovation pipeline positions India's biotech sector for the next generation of vaccines — including mRNA, viral vector, and intranasal platforms — as a developer, not just a manufacturer.